Indications of anakinra
Indications of anakinra
复制标题
DOI：
10.1016/j.lpm.2009.01.012
复制
发表时间：
2009-05-01
期刊：
影响因子：
2.7
通讯作者：
Fautrel, Bruno
中科院分区：
文献类型：
--
作者：
Chauffier, Karine;London, Jonathan;Fautrel, Bruno
阿那白滞素对 RA 相关症状和结构损伤的功效已在多项随机对照试验中得到证实。然而，它对其他生物制剂的兴趣似乎有限。在大剂量类固醇和甲氨蝶呤均失败后，阿那白滞素似乎有望用于治疗儿童或成人发病的斯蒂尔病。阿那白滞素在几种遗传性自身炎症综合征中的疗效显着。阿那白滞素可能是治疗中性粒细胞性皮肤病或复发性软骨炎的一种有趣的药物， 传统药物难以治疗。注射部位反应和感染是阿那白滞素相关的两种主要副作用。
The efficacy of anakinra on both RA-related symptoms and structural damage has been demonstrated in several randomized controlled trials. However, its interest seems limited with regards to other biologic agents.Anakinra seems promising in the treatment of childhood or adult onset Still disease, after the failure of both high dose steroids and methotrexate.The efficacy of anakinra is dramatic in several hereditary autoinflammatory syndromes.Anakinra could be an interesting drug for the treatment of neutrophilic dermatosis or relapsing chondritis, refractory to conventional agents.Injection site reactions and infections are the 2 main anakinra-related side effects.